Hartmut Link

14.0k total citations
142 papers, 5.1k citations indexed

About

Hartmut Link is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Hartmut Link has authored 142 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Hematology, 65 papers in Oncology and 23 papers in Genetics. Recurrent topics in Hartmut Link's work include Neutropenia and Cancer Infections (41 papers), Hematopoietic Stem Cell Transplantation (30 papers) and Acute Myeloid Leukemia Research (28 papers). Hartmut Link is often cited by papers focused on Neutropenia and Cancer Infections (41 papers), Hematopoietic Stem Cell Transplantation (30 papers) and Acute Myeloid Leukemia Research (28 papers). Hartmut Link collaborates with scholars based in Germany, United States and France. Hartmut Link's co-authors include Matti Aapro, Carsten Bokemeyer, Jan Foubert, Pierre Soubeyran, Lazzaro Repetto, Anders Österborg, A. Courdi, Augustin Ferrant, Georg Maschmeyer and Lubomir Arseniev and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Hartmut Link

128 papers receiving 4.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hartmut Link Germany 36 2.4k 1.9k 846 835 655 142 5.1k
F Mandelli Italy 28 1.9k 0.8× 1.7k 0.9× 586 0.7× 483 0.6× 919 1.4× 90 4.5k
Carole B. Miller United States 31 2.1k 0.9× 1.7k 0.9× 850 1.0× 1.0k 1.2× 1.0k 1.6× 108 5.2k
Gary Schoch United States 31 3.2k 1.3× 1.1k 0.6× 425 0.5× 1.0k 1.2× 527 0.8× 63 4.9k
Saroj Vadhan‐Raj United States 47 3.2k 1.3× 3.6k 1.8× 1.3k 1.5× 406 0.5× 982 1.5× 168 7.7k
David D. Hurd United States 35 2.4k 1.0× 1.6k 0.8× 1.2k 1.4× 381 0.5× 808 1.2× 159 4.8k
M. Boogaerts Belgium 38 2.2k 0.9× 1.2k 0.6× 572 0.7× 1.1k 1.3× 1.0k 1.5× 102 4.8k
Agnès Buzyn France 44 3.0k 1.2× 1.5k 0.8× 822 1.0× 715 0.9× 951 1.5× 137 5.7k
Hans A. Messner Canada 42 3.1k 1.3× 1.3k 0.7× 800 0.9× 622 0.7× 1.1k 1.8× 221 5.7k
John Pasi United Kingdom 41 3.7k 1.5× 769 0.4× 1.4k 1.6× 423 0.5× 837 1.3× 161 6.8k
Howard A. Liebman United States 47 3.4k 1.4× 1.0k 0.5× 979 1.2× 911 1.1× 996 1.5× 157 9.9k

Countries citing papers authored by Hartmut Link

Since Specialization
Citations

This map shows the geographic impact of Hartmut Link's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hartmut Link with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hartmut Link more than expected).

Fields of papers citing papers by Hartmut Link

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hartmut Link. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hartmut Link. The network helps show where Hartmut Link may publish in the future.

Co-authorship network of co-authors of Hartmut Link

This figure shows the co-authorship network connecting the top 25 collaborators of Hartmut Link. A scholar is included among the top collaborators of Hartmut Link based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hartmut Link. Hartmut Link is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Holch, Julian Walter, Sebastian Stintzing, Kathrin Heinrich, et al.. (2024). Refining first-line treatment decision in RAS wildtype (RAS-WT) metastatic colorectal cancer (mCRC) by combining clinical biomarkers: Results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).. Journal of Clinical Oncology. 42(3_suppl). 13–13. 1 indexed citations
2.
Aapro, Matti, Stephen Chaplin, Paul Cornes, et al.. (2023). Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer. Supportive Care in Cancer. 31(10). 581–581. 4 indexed citations
3.
Tesch, Hans, et al.. (2023). Ambulante Anämiediagnostik und -therapie. AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie. 58(4). 213–230.
4.
Link, Hartmut, et al.. (2019). Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany. Supportive Care in Cancer. 28(5). 2175–2184. 15 indexed citations
5.
6.
Folprecht, Gunnar, et al.. (2009). Phase II Trial of Capecitabine and Oxaliplatin in Patients with Adeno- and Undifferentiated Carcinoma of Unknown Primary. Oncology Research and Treatment. 32(4). 162–166. 14 indexed citations
7.
Aapro, Matti & Hartmut Link. (2008). September 2007 Update on EORTC Guidelines and Anemia Management with Erythropoiesis-Stimulating Agents. The Oncologist. 13(S3). 33–36. 124 indexed citations
8.
Link, Hartmut, C.-H. Köhne, Michael Stahl, et al.. (2008). Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. British Journal of Cancer. 100(1). 44–49. 55 indexed citations
9.
Link, Hartmut, et al.. (2006). Supportivtherapie bei malignen Erkrankungen. 1 indexed citations
10.
Knethen, Andreas von, et al.. (2005). Activation-Induced Depletion of Protein Kinase Cα Provokes Desensitization of Monocytes/Macrophages in Sepsis. The Journal of Immunology. 174(8). 4960–4965. 25 indexed citations
11.
Link, Hartmut, et al.. (1999). Reducing osteoporosis: prevention during childhood and adolescence.. PubMed. 77(5). 423–4. 11 indexed citations
12.
Link, Hartmut, Hans‐Jochem Kolb, Wolfram Ebell, et al.. (1997). Die Transplantation hämatopoetischer Stammzellen : Teil II: Indikationen zur Transplantation von hämatopoetischen Stammzellen nach myeloablativer Therapie (Übersicht). Medizinische Klinik - Intensivmedizin und Notfallmedizin. 92(9). 534–545. 3 indexed citations
13.
Link, Hartmut, Lubomir Arseniev, & H. Diedrich. (1996). Allogeneic bone marrow transplantation in a patient with Shwachman-Diamond syndrome. Annals of Hematology. 72(2). 83–84. 20 indexed citations
14.
Link, Hartmut & H. Diedrich. (1996). Introduction to the economics and mathematics of financial markets. Medical Entomology and Zoology. 91 Suppl 3. 3–17. 3 indexed citations
15.
Behre, Gerhard, et al.. (1995). Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Annals of Hematology. 71(6). 287–291. 3 indexed citations
16.
Freund, Mathias, et al.. (1991). Five-day 4′-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 117(5). 489–492. 3 indexed citations
17.
Ehninger, Gerhard, Mathias Freund, Gerhard Heil, et al.. (1990). Combination of Mitoxantrone and Etoposide in Patients Aged over 60 Years with Untreated Acute Myelogenous Leukemia. Hämatologie und Bluttransfusion. 33. 316–317. 5 indexed citations
18.
Kurrle, E., Gerhard Ehninger, M. Freund, et al.. (1990). Consolidation Therapy with High-Dose Cytosine Arabinoside: Experiences of a Prospective Study in Acute Myeloid Leukemia. Hämatologie und Bluttransfusion. 33. 254–260. 4 indexed citations
19.
Kurrle, E., Gerhard Ehninger, Mathias Freund, et al.. (1988). A multicentre study on intensive induction and consolidation therapy in acute myelogenous leukaemia. Annals of Hematology. 56(5). 233–236. 9 indexed citations
20.
Fiebig, Heinz‐Herbert, H. Henß, R. Engelhardt, et al.. (1983). Phase-II-Studie von AMSA bei Erwachsenen mit therapierefraktären akuten Leukämien. Oncology Research and Treatment. 6(4). 188–190. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by F Mandelli Breakdown of academic impact, for papers by Carole B. Miller Breakdown of academic impact, for papers by Gary Schoch Breakdown of academic impact, for papers by Saroj Vadhan‐Raj Breakdown of academic impact, for papers by David D. Hurd Breakdown of academic impact, for papers by M. Boogaerts Breakdown of academic impact, for papers by Agnès Buzyn Breakdown of academic impact, for papers by Hans A. Messner Breakdown of academic impact, for papers by John Pasi Breakdown of academic impact, for papers by Howard A. Liebman
Rankless by CCL
2026